Bicycle
Cambridge · Founded 2009 · 264 employees on LinkedIn · 7 known investors
Bicycle Therapeutics develops precision-guided therapeutics based on its proprietary bicyclic peptide (Bicycle) technology, designed to penetrate deep into tissues and target intractable solid tumor cancers. Beyond oncology, it collaborates with pharmaceutical partners and academic groups to apply the technology to other therapeutic areas including anti-infective, cardiovascular, ophthalmology, dementia, CNS, neuromuscular and respiratory conditions.
Founders & leadership
Bicycle was founded in 2009 by GREGORY WINTER.
GW
KL
KEVIN LEEinChief Executive Officer
NC
NIGEL CROCKETTinDistinguished Fellow
NK
NICHOLAS KEENExecutive
SA
SANTIAGO ARROYOinChief Development Officer (CDO)2023–2025
MH
MICHAEL HANNAYExecutive
MS
MICHAEL SKYNNERinChief Scientific Officer
Board
FJ
FELIX J. BAKERBoard director
RN
RICHARD N. KENDERBoard director
SS
STEPHEN SANDSBoard director
JG
JOSE-CARLOS GUTIERREZ-RAMOSBoard director
PL
PIERRE LEGAULTBoard director
Investors · 7
Ahren Innovation CapitalCambridge, Cambridgeshire
Astellas Venture Management LLCSouth San Francisco · $200K – $5M
Cambridge Innovation CapitalCambridge · $127K – $12.7M
Longwood FundBoston
SR One Capital ManagementRedwood City
SV Health InvestorsBoston · $1M – $20M
Vertex Ventures HCSingapore · $500K – $10M
Reported raises · per SEC filings
Form D private placements$555.5M disclosed across 1 round · 2024
▶$555.5MraisedJun 2024 · 19 investors · PharmaceuticalsRule 506(b)
▶$555.5MraisedJun 2024 · 19 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- KEVIN LEEExecutive Officer, Director
- FELIX J. BAKERDirector
- RICHARD N. KENDERDirector
- GREGORY WINTERDirector
- STEPHEN SANDSDirector
- NIGEL CROCKETTExecutive Officer
- JOSE-CARLOS GUTIERREZ-RAMOSDirector
- NICHOLAS KEENExecutive Officer
- SANTIAGO ARROYOExecutive Officer
- PIERRE LEGAULTDirector
- MICHAEL HANNAYExecutive Officer
- MICHAEL SKYNNERExecutive Officer
- ALISTAIR MILNESExecutive Officer
- ALETHIA YOUNGExecutive Officer
- JANICE BOURQUEDirector
- Offering amount
- $555.5M
- Amount sold
- $555.5M
- Sales commissions
- $10.1M
- Placement agents
- JEFFERIES LLC
- First sale
- May 2024
- Incorporated
- Other, United Kingdom
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
Frequently asked questions
- What does Bicycle do?
- Bicycle Therapeutics develops precision-guided therapeutics based on its proprietary bicyclic peptide (Bicycle) technology, designed to penetrate deep into tissues and target intractable solid tumor cancers. Beyond oncology, it collaborates with pharmaceutical partners and academic groups to apply the technology to other therapeutic areas including anti-infective, cardiovascular, ophthalmology, dementia, CNS, neuromuscular and respiratory conditions.
- Who founded Bicycle?
- Bicycle was founded by GREGORY WINTER in 2009.
- Who are Bicycle's investors?
- Bicycle's investors include Ahren Innovation Capital, Astellas Venture Management LLC, Cambridge Innovation Capital, Longwood Fund, SR One Capital Management, SV Health Investors, Vertex Ventures HC.
- How much funding has Bicycle raised?
- Bicycle has disclosed $555.5M raised across 1 round.
- Where is Bicycle headquartered?
- Bicycle is headquartered in Cambridge.